Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer Will Invest In Berkeley Site

by Michael McCoy
April 20, 2015 | A version of this story appeared in Volume 93, Issue 16

Bayer HealthCare will spend $100 million to build a hemophilia A product testing facility at its Berkeley, Calif., site. Bayer already conducts hemophilia A research and manufactures its Kogenate hemophilia treatment at the site. “The new product testing facility will test Bayer’s investigational products in accordance with rigorous global regulatory requirements,” says David Weinreich, head of global development for Bayer’s specialty medicine business.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.